Nightingale Health Oyj

Equities

HEALTH

FI4000490875

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Helsinki 11:29:56 2024-04-19 am EDT 5-day change 1st Jan Change
1.57 EUR +0.32% Intraday chart for Nightingale Health Oyj +44.04% +40.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Finland’s Nightingale Health Plots US Expansion MT
Nightingale Health to Establish A Laboratory in the United States CI
Nightingale Health and the Englander Institute for Precision Medicine At Weill Cornell Medicine Sign A Letter of Intent in Which the Parties Agree to Collaborate on the Adoption of Nightingale Health's Proprietary Technology in Healthcare and Medical Research in the United States CI
Nightingale Health Secures Blood Analysis Contract with Kaiser Foundation MT
Nightingale Health Enters into Agreement to Analyze 50,000 Blood Samples with Kaiser Foundation Health Plan, Inc CI
Nightingale Health Closes Purchase of Japan's Welltus MT
Nightingale Health Oyj completed the acquisition of Welltus Inc from Mitsui & Co., Ltd. and Kirin Holdings Company, Limited. CI
Nightingale Health plc Enters into an Agreement in Which It Will Analyze Blood Samples from Uganda's General Population Cohort CI
Finland-based Nightingale Health to Buy Japan's Welltus MT
Transcript : Nightingale Health Oyj, H1 2024 Earnings Call, Mar 07, 2024
Nightingale Health Oyj Reports Earnings Results for the Half Year Ended December 30, 2023 CI
Nightingale Health Oyj agreed to acquire Welltus Inc from Mitsui & Co., Ltd. and Kirin Holdings Company, Limited. CI
Singaporean Regulator Approves Nightingale Health's Blood Analysis Technology MT
Nightingale Health Oyj Receives Regulatory Approval for Healthcare Use from Health Sciences Authority in Singapore CI
Nightingale Health Lands Five New Health Risk Detection Patents in Finland MT
Nightingale Health plc Receives Five New Patents for Its Proprietary Health Risk Detection Capability CI
Suomen Terveystalo Begins Using Nightingale Health's Blood Analysis Technology in Regular Health Checks in Occupational Health CI
Terveystalo Integrates Nightingale Health's Blood Analysis Technology in Occupational Health MT
Nightingale Health Completes the Analysis of All 500,000 UK Biobank Samples Creating the Largest Blood Biomarker Database for Chronic Disease Research and Prevention CI
Nightingale Health plc Announces Maximilian Leroux Leaves as Chief Commercial Officer CI
Nightingale Health and Innoquest Diagnostics Enter into Collaboration Agreement to Make Nightingale Health's Technology Accessible in the Southeast Asia Region CI
Transcript : Nightingale Health Oyj, 2023 Earnings Call, Sep 28, 2023
Nightingale Health Oyj Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Nightingale Health Secures Three New Patents in Finland MT
Nightingale Health Receives Three New Patents Further Strengthening Its IP Portfolio CI
Chart Nightingale Health Oyj
More charts
Nightingale Health Oyj is a Finland-based health technology company that aims to promote preventative health and help people stay healthy. The blood analysis technology developed by Nightingale measures a broad group of biomarkers from a single blood sample, recognizing individual disease risks. The Company provides people with comprehensive insights on health, helps them make better decisions regarding their health and connects them with healthcare experts that offer preventative services for maintaining health. Nightingale Health Oy is the Parent Company in the Nightingale Group. The Group comprises the parent Company's subsidiaries: Nightingale Health United States Inc, Nightingale Health Asia Pte Ltd, Nightingale Health Japan KK as well as NG Health Sweden AB. The Company owns and independently oversees two laboratories in Finland, in Helsinki and Kuopio, and one laboratory in Tokyo, Japan.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.57 EUR
Average target price
1.25 EUR
Spread / Average Target
-20.38%
Consensus
  1. Stock Market
  2. Equities
  3. HEALTH Stock
  4. News Nightingale Health Oyj
  5. Nightingale Health To Buy Genetic Testing Firm Negen